TICKERNOMICS Sign up
Last Update: 2023-12-23 05:57:36
Edwards Lifesciences Corp ( EW ) https://www.edwards.com
74.95USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
EW
1.02%
SPY
30.72%
-15.10%
EW
SPY
112.82%
EW
60.70%
SPY
201.04%
EW
585.31%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
45682.03
45943.62
3.51
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
31.93
7.85
6.79
2.30
0.00
28.38
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
28.25
76.34
27.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.621
19.65
21.06
1.15
Other Earnings and Cash Flow Stats:
Edwards Lifesciences Corp ( EW ) Net Income TTM ($MM) is 1467.30
Edwards Lifesciences Corp ( EW ) Operating Income TTM ($MM) is 1657.00
Edwards Lifesciences Corp ( EW ) Owners' Earnings Annual ($MM) is 1190.41
Edwards Lifesciences Corp ( EW ) Current Price to Owners' Earnings ratio is 39.12
Edwards Lifesciences Corp ( EW ) EBITDA TTM ($MM) is 1799.20
Edwards Lifesciences Corp ( EW ) EBITDA Margin is 27.82%
Capital Allocation:
Edwards Lifesciences Corp ( EW ) has paid 0.00 dividends per share and bought back 15.0 million shares in the past 12 months
Edwards Lifesciences Corp ( EW ) has increased its debt by 5.0999999999998 million USD in the last 12 months
Capital Structure:
Edwards Lifesciences Corp ( EW ) Interest-bearing Debt ($MM) as of last quarter is 715
Edwards Lifesciences Corp ( EW ) Annual Working Capital Investments ($MM) are -1070
Edwards Lifesciences Corp ( EW ) Book Value ($MM) as of last quarter is 6727
Edwards Lifesciences Corp ( EW ) Debt/Capital as of last quarter is 10%
Other Balance Sheet Stats:
Edwards Lifesciences Corp ( EW ) has 1410 million in cash on hand as of last quarter
Edwards Lifesciences Corp ( EW ) has 1238 million of liabilities due within 12 months, and long term debt 596 as of last quarter
Edwards Lifesciences Corp ( EW ) has 609 common shares outstanding as of last quarter
Edwards Lifesciences Corp ( EW ) has 0 million USD of preferred stock value
Academic Scores:
Edwards Lifesciences Corp ( EW ) Altman Z-Score is 13.20 as of last quarter
Edwards Lifesciences Corp ( EW ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Edwards Lifesciences Corp ( EW ) largest shareholder is AllianceBernstein L.P. owning 20512235 shares at 1537.39 ($MM) value
Daveen Chopra(an insider) Sold 7000 shares of Edwards Lifesciences Corp ( EW ) for the amount of $547750.00 on 2023-12-15
0.85% of Edwards Lifesciences Corp ( EW ) is held by insiders, and 85.59% is held by institutions
Edwards Lifesciences Corp ( EW ) went public on 2000-03-27
Other Edwards Lifesciences Corp ( EW ) financial metrics:
FCF:1052.50
Unlevered Free Cash Flow:1010.70
EPS:2.53
Operating Margin:28.25
Gross Profit Margin:76.34
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:23.13
Beta:1.15
Buffet's Owners Earnings:1190.41
Price to Owner's Earnings:39.12
About Edwards Lifesciences Corp ( EW ) :
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.